Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

This study tests a combination of two drugs — zanubrutinib and rituximab — in people with a slow-growing (indolent) type of mantle cell lymphoma (MCL), a rare blood cancer. The goal is to see if this combination can control the disease without the need for aggressive chemotherapy. **You may be eligible if...** - You are 18 years or older - You have been confirmed to have mantle cell lymphoma with specific genetic markers - Your MCL is classified as "indolent" — meaning it is growing slowly and not causing severe symptoms - Your cancer is stage II–IV **You may NOT be eligible if...** - You have an aggressive form of mantle cell lymphoma - Your MCL does not have the required genetic marker (chromosome translocation or cyclin overexpression) - Your expected survival is less than 6 months Talk to your doctor to see if this trial is right for you.